Further postponement of approval of three FDA preparations of Huahai pharmaceutical

Huahai pharmaceutical said the company's three FDA preparation numbers are still waiting for FDA approval It is worth mentioning that the company previously said in a conference call that the three preparation products are expected to meet on April 30 According to the public information, the three preparation products are bupropion hydrochloride sustained-release tablets, levetiracetam sustained-release tablets and irbesartan hydrochlorothiazide compound preparations According to the public data, bupropion hydrochloride sustained-release tablets are mainly used for depression, levetiracetam sustained-release tablets are antiepileptic drugs, and irbesartan hydrochlorothiazide compound preparation is used for the treatment of essential hypertension "Now the FDA approval meeting will be held every week, and the products will be put on the market within one month after being approved," said the company's person, though he said it was difficult to estimate the sales of the three preparations after they were put on the market Huahai pharmaceutical industry is transforming from API to preparation business Because the company's preparation products are mainly generic drugs with "running volume", the sales scale depends on the number of preparation varieties to a large extent At present, the company has obtained 13 FDA preparation numbers through independent research and development and purchase According to Shenyin Wanguo Research Report, in 2013, the company realized a revenue of 300 million yuan from its own export preparations, accounting for 13% of the company's revenue.